Investor Relations

Investor Relations:

Our Mission:

At VydaMed, our mission is to provide non-invasive neuromodulation technology that helps people live stress-free. We help our patient population to live life without fear, in the calm and confidence we all deserve.

Our Vision:

Our vision is to be a leader of first-in-class, evidence-based, non-invasive medical device manufacturer to address the growing prevalence of anxiety and mood disorders worldwide. We aim to provide individuals access to effective tools and resources to improve their mental health and lead fulfilling lives.

Investment Opportunity:

VydaMed offers is a unique ground-level opportunity with a very large ROI that is estimated at 153 fold.

Request Additional Information:

    Do you sit on boards of medical device companies or have you previously invested in FDA-regulated medical devices?

    I am requesting a full business plan and am signing the NDA.


    1.THE PARTIES. This Non-Disclosure Agreement, hereinafter known as the “Agreement,” created this is by and between VydaMed, Inc, hereinafter known as “1st Party,” and , hereinafter known as “2nd Party,” and collectively known as the “Parties.”
    WHEREAS, this Agreement is created for the purpose of preventing the unauthorized disclosure of the confidential and proprietary information (the “Confidential Information”). The Parties agree as follows:

    Unilateral – This Agreement shall be Unilateral, whereas 1st Party shall have sole
    ownership of the Confidential Information with 2nd Party being prohibited from disclosing the Confidential Information to be released by the 1st Party.

    3.RELATIONSHIP. 1st Party’s relationship to 2nd Party can be described as
    Discloser, and 2nd Party’s relationship to 1st Party can be described as Recipient.

    4.DEFINITION OF CONFIDENTIAL INFORMATION. For the purposes of this Agreement, “Confidential Information” shall include, but not be limited to, documents, records, data, drawings, models, apparatus, sketches, designs, schedules, product plans, marketing plans, technical procedures, manufacturing processes, analyses, compilations, studies, software, prototypes, samples, formulas, methodologies, formulations, product developments, patent applications, know-how, experimental results, specifications, and other business information relating to the Party’s business, assets, operations, or contracts furnished to the other Party and/or the other Party’s affiliates, employees, officers, owners, agents, consultants, or representatives in the course of their work contemplated in this Agreement, regardless of whether such Confidential Information has been expressly designated as confidential or proprietary. Confidential Information also includes any and all work products, studies, and other materials prepared by or in the possession or control of the other Party, which contain, include, refer to, or otherwise reflect or are generated from any Confidential Information.

    However, Confidential Information does not include information that is: a) generally available to the public, b) widely used practices and/or algorithms, c) rightfully in the possession of the Parties prior to signing this Agreement, and d) independently developed or created without the use of any of the provided Confidential Information.

    5.OBLIGATIONS. The obligations of the Parties shall be to hold and maintain the Confidential Information in the strictest of confidence at all times and to their agents, employees, representatives, affiliates, and any other individual or entity that is on a “need to know” basis. If any such Confidential Information shall reach a third (3rd) party, or become public, all liability will be on the Party that is responsible. Neither Party shall, without the written approval of the other Party, publish, copy, or use the Confidential Information for their sole benefit. If requested, either Party shall be bound to return any and all materials to the Requesting Party within seven (7) days. This Section shall not apply to the 1st Party if this Agreement is Unilateral as marked in Section 2.

    6.TIME FRAME. The bounded Party’s(ies’) duty to hold the Confidential Information in confidence shall remain in effect for five (5) years.

    7.INTEGRATION. This Agreement expresses the complete understanding of the Parties with respect to the subject matter and supersedes all prior proposals, agreements, representations, and understandings. This Agreement may not be amended except in writing with the acknowledgment of the Parties.

    8.SEVERABILITY. If a court finds that any provision of this Agreement is invalid or unenforceable, the remainder of this Agreement shall be interpreted so as best to affect the intent of the Parties.

    9.ENFORCEMENT. The Parties acknowledge and agree that due to the unique and sensitive nature of the Confidential Information, any breach of this Agreement would cause irreparable harm for which damages and/or equitable relief may be sought. The harmed Party in this Agreement shall be entitled to all remedies available at law.

    10.GOVERNING LAW. This Agreement shall be governed under the laws in the State of New York.

    WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date written below.

    Eyad Kishawi

    1st Party’s Printed Name

    Eyad Kishawi

    1st Party’s Signature


    2nd Party’s Printed Name

    2nd Party’s Signature



    There are approximately 300 million people diagnosed with an anxiety disorder worldwide.

    Anxiety Epidemic in the US

    Amidst an unprecedented surge in anxiety levels across the US, the nation has earned the unenviable title of the most anxious country in the world, with no sign of abatement. The severity of this issue becomes evident when considering that one in eight children are affected by anxiety disorders, with a prevalence of severe anxiety disorder reaching 5.9% over their lifetime.

    The impact extends to the broader population, with about 105 million experiencing mild to severe anxiety at some point in their life. Further, it is stated that 19% of adults are diagnosed with an anxiety disorder across the US, and since the COVID-19 pandemic, global anxiety has increased by 25%. Veterans and individuals with attention-deficit disorder, autism spectrum disorder and post-traumatic stress disorder also face health needs that often intertwine with anxiety and other mental health conditions.

    There is a shortage of therapists to meet the growing demand, and psychiatrists are picking up the slack, thus resulting in more drug prescriptions. Parents of children ages 12 – 18 who are diagnosed with an anxiety disorder are frustrated that they can’t find their children effective relief. Their children frequently change therapists and are prescribed multiple medications, some of which are psychotropic and have severe side effects. Therapy is expensive and often non-reimbursed. Finding a good therapist may be difficult. Parents express concern over their children’s growing brains and the effect of medications and non-continuous therapy.


    Market segmentation for the device:

    Target Market: 361K parents of children diagnosed with an anxiety disorder who are in therapy and psychiatry, $179M+.

    Serviceable Available Market: 65.1M US citizens diagnosed with an anxiety disorder, $32B+.

    Total Global Available Market: 300M people worldwide diagnosed with an anxiety disorder, $149B+.

    Business Model

    VydaMed will primarily generate revenue through one-time hardware sales and recurring subscription fees. Customers will make a one-time payment of $349.00 for the wearable hardware. Additionally, there is an annual subscription cost of $99.00 for the required companion application, providing users with ongoing support and monitoring. In comparison, a single visit to a therapist could cost around $150-$200.


    App and wearable operate over Bluetooth in a closed-loop feedback system to regulate relaxation and alertness equilibrium. The wearable targets the parasympathetic nervous system while it uses physiologic parameters with proprietary signal processing methods as the control variable. This loop provides extrinsic and objective anxiety control.

    The App running on a smartphone also has logging capability and push notifications to alert the user of possible changes in emotional states. The App features dialectical behavioral therapy techniques that allow the user to intrinsically take control over their emotional state. The App, which works between therapy and psychiatric visits, will be the "therapist's best friend", as it will help both provider and patient explore trigger points and coping mechanisms.

    With both extrinsic control, augmenting medications, and intrinsic control, augmenting therapy, VydaMed will leverage neural plasticity to place the patient in the driver's seat so that common triggers do not result in stressful and overwhelming responses.